Mayo Clinic Identifies Five Distinct Forms of Fatty Liver Disease
New research reveals that fatty liver disease comprises five unique subtypes, each with varying health risks.
Fatty liver disease, affecting nearly 30% of adults, has five distinct subtypes.
Genetic factors significantly influence the progression of liver damage.
Future treatments may be tailored based on the specific subtype of the disease.
On October 18, 2026, researchers at the Mayo Clinic announced a groundbreaking discovery regarding fatty liver disease, revealing that it consists of five distinct biological subtypes. This common liver condition, which affects approximately 30% of adults globally, has been found to carry varying risks for serious health complications, including liver failure, cancer, and cardiovascular diseases.
The study, published in Nature Communications, emerged from a collaboration between Mayo Clinic and Virginia Tech. Researchers focused on metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease. They identified that MASLD can arise from multiple biological pathways, some linked to obesity and diabetes, while others are influenced by genetic predispositions.
A significant finding of the research is the identification of genetic subtypes of MASLD, which are associated with a higher likelihood of severe liver damage, even among individuals without traditional metabolic risk factors. This insight could lead to earlier detection and more personalized treatment strategies for patients, as noted by Shulan Tian, Ph.D., a co-senior author of the study.
The implications of this research are profound, as understanding the different subtypes of fatty liver disease could enhance screening processes and treatment plans. The study also revealed connections between certain MASLD subtypes and other health issues such as depression and sleep apnea, suggesting a broader impact on overall health beyond liver function.
Looking ahead, the research team aims to validate their findings in larger, more diverse populations and explore how different subtypes respond to existing treatments. This could pave the way for more precise interventions and improved patient outcomes in managing fatty liver disease.
